NKX3-1 and central nervous system cancer: CCK assay results showed that, when compared to the control group, the lncRNA NKX3-1 overexpression group significantly increased the proliferation ability of glioma cells at 48, 72, and 96 h (P <0.05), whereas the proliferation ability of glioma cells in the lncRNA NKX3-1 knockdown group significantly decreased at 48, 72, and 96 h (P <0.05), as shown in Figure 6A.